Safety and immunogenicity of the Mycobacterium tuberculosis ΔlysA ΔpanCD vaccine in domestic cats infected with feline immunodeficiency virus

Dawn M. Zimmerman, W. Ray Waters, Konstantin P. Lyashchenko, Brian J. Nonnecke, Douglas L. Armstrong, William R. Jacobs, Michelle H. Larsen, Erin Egan, Gregg A. Dean

Research output: Contribution to journalArticle

7 Scopus citations

Abstract

Feline immunodeficiency virus (FIV)-positive and FIV-negative cats (n = 4/group) received 2 × 106 CFU Mycobacterium tuberculosis ΔlysA ΔpanCD intramuscularly. Vaccination elicited antibody responses, albeit at lower levels in FIV-positive cats than in FIV-negative cats. Delayed-type hypersensitivity responses were minimal in both groups. No adverse reactions were found.

Original languageEnglish (US)
Pages (from-to)427-429
Number of pages3
JournalClinical and Vaccine Immunology
Volume16
Issue number3
DOIs
StatePublished - Mar 1 2009

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Clinical Biochemistry
  • Microbiology (medical)

Fingerprint Dive into the research topics of 'Safety and immunogenicity of the Mycobacterium tuberculosis ΔlysA ΔpanCD vaccine in domestic cats infected with feline immunodeficiency virus'. Together they form a unique fingerprint.

  • Cite this